Airsculpt Technologies, Inc.: insider trades · United States · SEC (Form 4)

About Airsculpt Technologies, Inc.

AirSculpt Technologies, Inc. is a United States-based company listed on the NASDAQ market under the ticker AIRS. It operates in the aesthetic healthcare space and focuses on premium body contouring procedures. The company’s core offering is a minimally invasive treatment platform designed to remove fat, tighten skin and reshape targeted areas of the body with a strong emphasis on precision, comfort and recovery speed. In its regulatory and investor materials, AirSculpt describes itself as a national provider of premium body contouring procedures delivered exclusively through its own offices and supported by surgeons, nurses and patient care consultants. ([investors.airsculpt.com](https://investors.airsculpt.com/static-files/0480fb6a-a699-41e0-888f-2e9fc33f246b)) Founded in 2012, AirSculpt is headquartered in Miami Beach, Florida, in the United States. The business is structured around AirSculpt Technologies, Inc. and its subsidiaries, with a vertically controlled model that combines proprietary medical procedures, standardized patient experience and a branded service format. The company’s flagship method, AirSculpt®, is presented as a patented, next-generation body contouring technology that is minimally invasive and does not require needles, scalpels, stitches or general anesthesia. This proprietary positioning is a key competitive differentiator versus more traditional cosmetic surgery providers. ([investors.airsculpt.com](https://investors.airsculpt.com/static-files/0480fb6a-a699-41e0-888f-2e9fc33f246b)) Its main service lines include a broad range of fat removal and fat transfer procedures. AirSculpt markets several branded treatments, including AirSculpt®, AirSculpt® +, AirSculpt® Smooth, Power BBL®, Up a Cup™ and Hip Flip™. AirSculpt® + combines fat removal with skin tightening, while AirSculpt® Smooth is designed to reduce cellulite. These offerings indicate that the company is not just selling a single procedure, but rather building a portfolio of proprietary aesthetic solutions aimed at different patient needs within the body-contouring category. ([investors.airsculpt.com](https://investors.airsculpt.com/static-files/0480fb6a-a699-41e0-888f-2e9fc33f246b)) Geographically, the company’s footprint is primarily in the United States, with an additional presence in Canada. Recent disclosures also show a strategic retrenchment abroad, including the closure of its London facility in 2025, suggesting management is focusing capital and operational attention on the most attractive markets. In early 2026, management also highlighted a refreshed go-to-market strategy, improved business processes and the launch of new procedures as part of efforts to reaccelerate growth. ([investors.airsculpt.com](https://investors.airsculpt.com/static-files/0480fb6a-a699-41e0-888f-2e9fc33f246b)) Recent operating trends point to a company in turnaround mode. In 2025, AirSculpt completed 11,852 procedures and reported revenue of $151.8 million, down from 2024. In April 2026, management reported sequential improvement in same-store sales and provided full-year 2026 guidance for approximately $151 million to $157 million in revenue and $15 million to $17 million in Adjusted EBITDA. From an investment perspective, AirSculpt remains a niche aesthetic-healthcare operator with a differentiated brand and proprietary procedures, but it also faces demand cyclicality and execution risk as it works to stabilize growth and improve profitability. ([investors.elitebodysculpture.com](https://investors.elitebodysculpture.com/node/8641/pdf))